A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer

Research output: Contribution to journalArticle

Abstract

Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC.

Original languageEnglish
Pages (from-to)495-503
Number of pages9
JournalEMBO Molecular Medicine
Volume3
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

MicroRNAs
Routine Diagnostic Tests
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Serum
Population
Early Diagnosis
Neoplasms
Tomography
Mortality

Keywords

  • Diagnosis
  • Early stage
  • Lung cancer
  • MiRNA
  • Serum

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

@article{c876853f0b454f688351b990853e5f8a,
title = "A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer",
abstract = "Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80{\%} accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC.",
keywords = "Diagnosis, Early stage, Lung cancer, MiRNA, Serum",
author = "Fabrizio Bianchi and Francesco Nicassio and Matteo Marzi and Elena Belloni and Valentina Dall'Olio and Loris Bernard and Giuseppe Pelosi and Patrick Maisonneuve and Giulia Veronesi and {Di Fiore}, {Pier Paolo}",
year = "2011",
month = "8",
doi = "10.1002/emmm.201100154",
language = "English",
volume = "3",
pages = "495--503",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer

AU - Bianchi, Fabrizio

AU - Nicassio, Francesco

AU - Marzi, Matteo

AU - Belloni, Elena

AU - Dall'Olio, Valentina

AU - Bernard, Loris

AU - Pelosi, Giuseppe

AU - Maisonneuve, Patrick

AU - Veronesi, Giulia

AU - Di Fiore, Pier Paolo

PY - 2011/8

Y1 - 2011/8

N2 - Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC.

AB - Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC.

KW - Diagnosis

KW - Early stage

KW - Lung cancer

KW - MiRNA

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=79960957682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960957682&partnerID=8YFLogxK

U2 - 10.1002/emmm.201100154

DO - 10.1002/emmm.201100154

M3 - Article

C2 - 21744498

AN - SCOPUS:79960957682

VL - 3

SP - 495

EP - 503

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 8

ER -